EirGenix Inc. operates as a contract development and manufacturing company in Taiwan and internationally. The company offers cell line development, process development, analytical and quality control, cGMP manufacturing mammalian and microbial system, and antibody-drug conjugate services. It is also involved in the development of EG12014/EGI014, a Trastuzumab biosimilar, indicated for the treatment of cancer and currently under biologics license application status; EG1206A, a Pertuzumab biosimilar, indicated for the treatment of cancer and currently under Phase I stage; EG13074, indicated for the treatment of cancer and currently under Preclinical stage; TSY0110(EG12043), an antibody-drug conjugate, indicated for the treatment of cancer and currently under Preclinical stage; EG12021, Bevacizumab biosimilar, indicated for the treatment of cancer and currently under Preclinical stage; and EG62054, a biosimilar, currently under Preclinical stage. In addition, the company manufactures and sells covid-19 antigen rapid test; and EG74032, a CRM197 carrier protein. The company was incorporated in 2012 and is headquartered in New Taipei City, Taiwan.
तुलना करने के लिए मीट्रिक्स | 6589 | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंध6589पीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −18.1x | −1.4x | −0.5x | |
PEG अनुपात | 1.79 | 0.01 | 0.00 | |
क़ीमत/बुक | 1.7x | 1.4x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 13.7x | 1.5x | 3.2x | |
अपसाइड (विश्लेषक लक्ष्य) | 199.3% | 65.6% | 47.4% | |
उचित मूल्य अपसाइड | अनलॉक करें | 24.1% | 6.9% | अनलॉक करें |